Sign In
Last checked at 
22 Oct 2020 07:00
IXICO plc
("IXICO" or the "Company")
Further Huntington's disease contracts
Additional Huntington's disease contracts with new and existing large pharma clients
IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has secured new contracts in Huntington's disease (HD) clinical trials.
The new contracts include retrospective analysis of data sets for three Natural History Studies in Huntington's disease with a new large pharma customer and a multicentre, open-label Phase II study in Huntington's disease with an existing large pharma customer.
Whilst these contracts to support HD clinical trials are not to the same scale as the £10.5m contract announced in April 2020, these additional contracts reflect the strong position IXICO has as a trusted neuroscience technology partner in this area. These contracts do not have significant impact on management's expectations of performance for the year but contribute to the Company's strong order book. In addition to this, these contracts are for early stage clinical trials and, as already demonstrated, IXICO has a strong track record of following clinical assets through to phase III where the contracts generate greater revenues.
Giulio Cerroni, Chief Executive Officer of IXICO, commented: "Huntington's disease is a devastating rare neurological condition with unmet medical needs. IXICO has worked on several HD clinical studies since 2007 and is pleased to build further momentum in our mission to support our clients in delivering data analytics in these challenging areas of rare, neurodegenerative disease. Our services will enable clients to measure the impact of the trialled drugs with greater confidence and potentially unlock new insights into disease progression and drug development."
For further information please contact:
IXICO plc | +44 (0)20 3763 7498 | |||
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |||
|
| |||
Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |||
Giles Balleny / Max Gould (Corporate Finance) |
| |||
Michael F Johnson / Russell Kerr (Sales) |
| |||
|
| |||
Walbrook PR Ltd | +44 (0)20 7933 8780 | |||
Paul McManus / Lianne Cawthorne / | IXICO@walbrookpr.com | |||
Alice Woodings
|
| |||
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IxicOplc
Follow the stocks
